Day 2 :
Keynote Forum
Stef Stienstra
Civil-Military-Interaction-Command Royal Dutch Armed Forces, Netherlands
Keynote: Zoonotic diseases threat needs sharing of information and new diagnostic systems in less developed countries
Time : 09:30-10:00
Biography:
Works internationally for several medical and biotech companies as a scientific advisory board member and is also an active reserve-officer of the Royal Dutch Navy in his rank as Commander (OF4). For the Dutch Armed Forces, he is CBRNE specialist with a focus on (micro)biological and chemical threats and medical- and environmental functional specialist within the 1st CMI (Civil-Military Interaction) Battalion of the Dutch Armed Forces. For Expertise France he is now managing an EU CBRN CoE public health project in West Africa. He is visiting a professor at the University of Rome Tor Vergata giving lectures for the CBRN Master study. In his civilian position, he is at this moment developing with MT-Derm in Berlin (Germany) a novel intradermal vaccination technology as well as a new therapy for cutaneous leishmaniasis for which he has won a Canadian ‘Grand Challenge’ grant. With Hemanua in Dublin (Ireland) he has developed an innovative blood separation unit, which is also suitable to produce convalescent plasma for Ebola Virus Disease therapy. He has finished both his studies in Medicine and in Biochemistry in The Netherlands with a doctorate and has extensive practical experience in cell biology, immuno-hematology, infectious diseases, biodefense, and transfusion medicine.
Abstract:
Sharing public health threat information is a necessity for governments to prevent outbreaks of infectious diseases. Zoonotic diseases are the most dangerous for outbreaks running out of control, as the population does not have natural nor artificial (from vaccination) immune response to new emerging diseases. The recent Ebola Virus Disease outbreak in West Africa was such an example. New diagnostic methods, which can be performed in developing countries lacking critical infrastructure have to be developed to have an early response on (potential) outbreaks. It must be high tech with high reliability, which can be used in rural areas without proper infrastructure. The mitigation of highly infectious and deadly disease pandemics have to be recognized at the source. Sophisticated diagnostic equipment and good calibration, maintenance and interpretation of the results is essential. To identify pathogens at molecular level new technologies are under development. In developing countries military and civilian actors cooperate fruitfully in fighting potential biological threats. In this civil-military cooperation it is not only the biosafety, which has to be considered, but also the biosecurity, as misuse of extremely dangerous strains of microorganisms cannot be excluded. Several zoonotic infectious diseases, like anthrax, small pox and also the hemorrhagic fevers like Ebola Virus Disease are listed as potential bioweapons. With this extra threat in mind, both biosafety and biosecurity have to be implemented in all mobile or fixed clinical laboratories. An information/computer network with a cloud in which essential information can be traced, helps in early detection of outbreaks of ‘new’, mostly zoonotic, infectious diseases. The same technology helps in the forensic aspects in case of a bioterror attack.
Keynote Forum
Sugga Gurfateh Singh
Rayat Bahra University, India
Keynote: Current scenario of clinical trials in India
Time : 10:00-10:30
Biography:
I am an Assoc. Prof. in Department of Pharmacology, University School of Pharmaceutical Sciences, Rayat Bahra University & associated more than 12 years with Teaching/Research/Pharmacy field and guided more than 60 UG, PG & Ph.D Scholars. Moreover I have published 54 International/National research/review papers and attended more than 35 International/National conferences as Speaker/Resource Person/Chairpersons. I have published two books and organized more than 5 national conferences as LOC member. I received various prestigious academic appreciations & awards like Best Student Award, Young Scientist Award and Best Poster Presentation Awards. Moreover I am members of various Scientific and Professional Societies like Indian Pharmacological Society, Indian Pharmacy Graduates Association, Society of Pharmaceutical Education & Research, and Association of Pharmaceutical Teachers of India.
Abstract:
- Immunology Research |Clinical Trials for Diseases |Case Report in Clinical Trials |Virology Research |Monoclonal Antibodies
Location: Red Cedar Ballroom C
Chair
Rongtuan Lin
McGill University, Canada
Session Introduction
Wenping Gong
The 309th Hospital of PLA, China
Title: The current status, challenges and future developments of new tuberculosis vaccines
Time : 10:45-11:10
Biography:
Abstract:
Cheng-Chuan Su
Tzu Chi University, Taiwan
Title: Human Herpesvirus type 8 in patients with chronic hepatitis
Time : 11:10-11:35
Biography:
Abstract:
Luo Yanping
General Hospital of Chinese PLA, China
Title: Analysis of antimicrobial resistance and risk factors of hospital acquired methicillin-resistant Staphylococcus aureus infection
Biography:
Abstract:
Iqbal Sami
TB Hospital Sardogha, Pakistan
Title: Role of treatment supporter in control of T.B through T.B control program working in district Sargodha Punjab Pakistan
Biography:
Abstract:
Objectives: To evaluate the role of treatment supporter and their impact on patient treatment come out.
Material/Methods: The study was a cross sectionals survey in the routine T.B control program operational context. 200 smears positive. T.B patient were diagnosed and registered in T.B hospital Sargodha in one year 2016. With available come out were included in the study.
Results: The majority of patients (95%) were provided the treatment supporter, most of treatment supporter were (60%) LHW (9%) are community volunteers and (28%) are family members and (3%) are health facility worker. A total of 87% categorized as treatment success and (4%) transferred out (3.5%) expired and (4.5%) defaulted and 1% treatment failure.
Conclusion: The overall treatment success rate was (87%) and significantly high treatment success rate was (90%) in patient supervised by LHW compared to other patients.
Biography:
Abstract:
Pap smear is a good sample for identification of abnormalities in the cervix. Basic advantages are easy to handle and transport. After receiving the smears to the relevant lab, the medical laboratory technologists have to accept the samples and do the staining procedures. The technologist's responsibility is issuing the reports within 14 days. Because of that rule( issuing date) technologists have to work hard and fast. So difficult to get an ideal conclusion about the smear. (a) Deuto that time of period, some time they apply shortcuts in the staining procedures. They keep the short time period in the running tap water bath for the washing step. That hence excess hematoxylin staining particles will remain on the smear. So that nuclei and the chromatin cannot be seen very clearly. The other one is, they do not use Scott's tap water for the blueing. Nuclear chromatin is a very important factor from which get more information about the abnormal cells. Scott's tap water act as clearing agent and gives more blue contrast. Early abnormalities in the cervix can be missed when the application of the incomplete staining techniques. (b) Some smears covered with 60% of blood. So that is very difficult to find abnormal hypochromic cells. When they don't pay their attention that abnormal cells can be missed. It also misleads the negative results. (c) Some smears are overcrowded. Because they made it using a small part of the slide surface. All the normal and abnormal cells are in the one cells clump. When the screening the smear cannot go through the one by one cell. It also misleads the negative result. (d) Candida infection: In that infection cells get somewhat enlarge. When the screening, once they look candida organism in the smear, they consider only candida infection not the changes of the HPV. Some pap smears having both candida infection and HPV changes. But screeners report candida infection only.
Conclusions: (1) Due to that points, a Qualified technologist with experience must re-examine the random samples from every 100 slides of the negatives. (2) Medical laboratory technologist should be examined 25 slides for the day. Not more than that because they need more time to screen and make a good report.
Results: 2-4% of new cases can be found the form that negatives within 6 months. I think false positives better than false negatives. Because very positives patients who had a low-grade squamous intraepithelial lesion or atypical squamous cells of undetermined significance (ascus) have to repeat their second sample within six months.
- Poster session
Location: Red Cedar Ballroom C
Chair
Gurfateh Singh
Rayat Bahra University, India
Session Introduction
Suliman Qadir Afridi
Technische Universität München, Germany
Title: Longitudinal evolution of norovirus in chronically infected patients
Biography:
Suliman Qadir Afridi has received his BSc and MSc in microbiology and virology and now he is doing his PhD at the Institute of Virology, Technische Universität München (TUM), Germany. He is a DAAD scholar. He has published 3 papers in reputed journals.
Abstract:
Naser Nazari
Kermanshah University of Medical Sciences, Iran
Title: Epidemiological study of cutaneous leishmaniases in cities of Kermanshah province, Iran
Biography:
Naser Nazari has completed his PhD at the age of 42 years from Sheffield University in England and he is working at Kermanshah University, School of Medicine for 10 years. He is head of the department of Parasitology and Mycology, medical school as an associated professor. He has published more than 20 papers in reputed journals
Abstract:
Zhang Youjiang
General Hospital of Chinese PLA, China
Title: The main pathogenic bacteria distribution and drug resistance analysis of common surgical infection in general surgery
Biography:
Abstract:
Objective: To retrospectively investigate the distribution and drug resistance of the main pathogens of common surgical infections in general surgery and to provide references for early and reasonable empirical treatment. Methods: The pathogens of the infected tissues, sputum, peritoneal drainage and puncture fluid were collected and identified in our hospital from January 2012 to January 2016. The pathogen type, distribution, and drug resistance were analyzed. Results: A total of 628 strains of pathogens were co-cultured in 397 infected patients. Among the 323 strains of pathogens, Escherichia coli and Klebsiella pneumoniae were 27.55% and 19.20% respectively. The number of pathogens isolated from the sputum samples was 213, and were Klebsiella pneumoniae, Pseudomonas aeruginosa, and Acinetobacter baumannii predominantly, accounting for 44.60%, 17.37%, and 13.62% respectively. 92 strains of pathogens were isolated from intraperitoneal drainage and puncture fluid samples. Escherichia coli and Klebsiella pneumoniae were mainly accounted for 45.65% and 10.87% respectively. Klebsiella pneumoniae, Escherichia coli are highly sensitive to imipenem and meropenem. Enterococcus faecalis is resistant to vancomycin. Pseudomonas aeruginosa in addition to cefazolin and other antibacterial drugs other than ceftriaxone are more sensitive, and Acinetobacter baumannii was with highly multiple drug resistance. Conclusions: Patients with common surgical infection should be mainly Gram-negative bacilli, which are sensitive to carbapenem antibiotics and should be promptly inspected and selected according to the distribution of pathogens and drug susceptibility.
Wenya Huang
National Cheng Kung University, Taiwan
Title: Development of hepatitis B virus large surface protein pre-S2 mutant ELISA assay for predicting hepatoma risk in chronic carriers
Biography:
Abstract:
Chronic hepatitis B virus infection is a major cause of HCC worldwide. Long-term monitoring of high-risk markers in chronic HBV carriers is important to identify the ones that need frequent follow-up or uptake prophylactic therapies. Though up to now the methods (e.g. ultrasound) and tumor markers (e.g. alpha-fetal protein) to diagnose HCC has been established, the high-risk markers for HCC incidence and recurrence have not been fully identified, given that HCC tumorigenesis is a complex process regulated by various crosstalks between host and viral factors. The pre-S2 deletion mutant large HBS (LHBS), isolated from the type 2 ground glass hepatocyte, has been found highly associated with HCC. To detect the pre-S deletion in LHBS, we developed a pre-S Gene Chip, which detects the pre-S deletion based on DNA hybridization of the HBS genes in patients to the DNA probes on the chip. We have also recently pursued to develop the ELISA system and sought its clinical application to test the pre-S2 mutant LHBS in clinical serum samples. The performances of the detection systems in clinical specimens have been validated. The products of monoclonal antibodies and respective ELISA systems, as well as Pre-S Gene Chip, have gained the US and Taiwan patent approval. Using these detection methods, we have identified the pre-S2 mutant LHBS as a predictive marker for HCC recurrence after the receiving hepatectomy surgeries.